This week in MedTech, funding rounds focused around intelligent diagnostics, neurotechnology, and connected care platforms as companies push toward clinical adoption and international expansion. Read more below.
RaysightMed secures nearly RMB 100M series D to advance precision cardiac diagnosis
The RMB 100M ($14.7M) financing validates RaysightMed’s core technology, commercial progress, and industrial value, while supporting pipeline development, business growth, and international expansion.
The company will also accelerate development of its AI-driven vascular interventional robotic platform and integrated AI-powered diagnostic and therapeutic solutions.
CEO Zheng Lingxiao
Last week’s tracker: Cagent, Sound Wave & more
Zentek announces closing of fully subscribed brokered LIFE Offering of C$18M
Zentek announced the closing of its previously announced “best efforts” private placement for gross proceeds of C$18M ($13M) which includes the exercise in full of the agent’s option.
Pursuant to the Offering, the company sold 18,000,000 units of the company at a price of C$1.00 per unit. Red Cloud Securities Inc. acted as sole agent and bookrunner in connection with the Offering.
CEO Mohammed Jiwan
MindMaze Therapeutics announces CHF 8.0M strategic Equity financing
MindMaze Therapeutics Holding SA announced it has entered into a definitive agreement for a CHF 8.0M ($10M) equity financing with Neuro.io Group SA (Neuro.io), through which Neuro.io will acquire a strategic equity position in the Company.
The proceeds will support the Company’s commercial priorities, including scaling its U.S. footprint and advancing deployment of its neurotherapeutics solutions.
CEO Zach Henderson
Oli raises $6.5M to predict birth complications before they happen
Oli has raised $6.5M in a Series A3 funding round to accelerate the development of its maternal and fetal monitoring technology, designed to predict and reduce birth complications before they occur.
The Sydney-based startup was backed by Scale Investors, Clare Ventures, and the University of Sydney in the round.
CEO Tara Croft
ThIA Santé Mentale raises €5M to scale AviPsy
ThIA Santé Mentale completed a second round of funding of 5 million euros from IRDI Capital Investissement, Sofilaro Innovation, insurers Generali and AG2R la Mondiale, private investors (via the Tudigo platform) and partner practitioners.
The startup has developed AviPsy, a digital platform designed to streamline access to mental health care.
CEO Frédérique Mozziconacci
ReVision Implant raise €4M for a vision device that feeds directly into your brain
The company has closed a €4M oversubscribed round from private investors, including existing backers and new European medtech operators and business leaders. No single lead investor was named.
The raise adds to ReVision’s existing public funding, which includes EU grants totalling nearly €1.5M across the EIC Pathfinder Hyperstim project and the €2.4M EIC Transition FlairVision project, bringing total publicly disclosed funding to over €5.4M.
CEO Frederik Ceyssens
Xiao Chuang Medical Treatment secures Angel+ financing
The round was led by Oriza Holdings, followed by Suzhou High-tech Zone Sci-Tech Innovation Angel Fund and Shanghai Hongye.
The proceeds will be primarily used to advance the clinical trial process of its core product and accelerate commercial implementation.
